ClinicalTrials.gov
public full text
Public Domain
Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia
The purpose of the study is to determine the maximum tolerated dose of ribavirin, when given in combination with low-dose ara-C and to determine if it is safe and well-tolerated in patients with acute myeloid leukemia.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)#1152752
- RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.#910351
- Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML#969431
- Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia#1164506
- RIBA Research in Practice Guide#231200
Record · ID 1074002
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive